# A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

> **NCT04576455** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 303 (actual)

## Conditions studied

- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Giredestrant
- **DRUG:** Fulvestrant or an Aromatase Inhibitor (Physician Choice)
- **DRUG:** LHRH Agonist

## Key facts

- **NCT ID:** NCT04576455
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-27
- **Primary completion:** 2022-02-18
- **Final completion:** 2027-08-25
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04576455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04576455, "A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04576455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*